Selected Quotes from The Street, Inc.

It is a great honor for us at TheStreet to be of service through education.” -Elisabeth DeMarse, Chairman and CEO of TheStreet, Inc. 

Since our founding, has strived to maintain the highest integrity in all of our pursuits” he said. “This is especially true with initiatives that involve our readers.” – David Morrow, editor-in-chief of

June 22, 2015 – Open Letter to Board of Directors, The Street, Inc. – RE: Possible Fiduciary Breach of Duty of Loyalty & Duty of Care by The Board of Directors of the Street, Inc., a publicly traded corporation

Our first priority is growing our subscription newsletter business.”  – Elisabeth DeMarse, President CEO & Chairman of The Street, Inc.

June 17, 2015 – Open Letter to Ms. Edith Ramirez, Chairwoman, Federal Trade Commission – Re: The Street, Inc. possible Nationwide Advertising Fraud & Deception possibly causing irreparable harm against innumerable U.S. Citizens and IsoRay, Inc. a company domiciled in Washington State

We’re proud to have TheStreet’s founder, Jim Cramer, under contract,” she said. “He is a committed member of our team and is appropriately aligned with the success, growth and profitability of the firm.” – Elisabeth DeMarse, President CEO & Chairman of The Street, Inc.

Jim (Cramer) I would say, yeah sure Jim were no Bear Stearns but I think were going to do OK. Jim I think recommended Bear Stearns, Leahman and other things, so frankly he is a contra indicator” -Elon Musk   Note: This quote was made by Mr. Elon Musk when Tesla (TSLA) was approximately $17.00 a share and the stock is now trading at $279.72 a share, Bear Stearns is now worth $0.00 a share.

Company filings show that Cramer is guaranteed at least $2.5 million a year in royalties, another $300,000 in licensing, as well as stock awards.

June 9, 2015 – Open Letter to The Street, Inc., CEO & Chairman, Ms Elisabeth H DeMarse – Re: Failure to retract possibly false and slanderous statements made by Mr. Adam Feurestein and within an article published on May 21, 2015 entitled:’ IsoRay Takes Liberties With Lung Cancer Study Results to Prop Up Stock Price ‘